brolucizumab

Brolucizumab is a humanized recombinant monoclonal antibody fragment (single-chain variable fragment, scFv) that acts as a vascular endothelial growth factor A (VEGF-A) inhibitor. It binds to the three major isoforms of VEGF-A (VEGF110, VEGF121, and VEGF165), preventing their interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A signaling, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability in the eye. This mechanism reduces abnormal blood vessel growth and leakage associated with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). Brolucizumab is administered by intravitreal injection for these indications[1][2][6].

Brand names

Beovu

Other names

brolucizumab-dbll